These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27162295)

  • 21. Current strategies in the management of lysosomal storage diseases.
    Heese BA
    Semin Pediatr Neurol; 2008 Sep; 15(3):119-26. PubMed ID: 18708002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in treatment approaches of lysosomal storage diseases (LSDs).
    Rozenfeld PA
    Curr Pharm Biotechnol; 2011 Jun; 12(6):853. PubMed ID: 21506916
    [No Abstract]   [Full Text] [Related]  

  • 23. Emerging drugs for lysosomal storage diseases.
    Beck M
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):495-507. PubMed ID: 20557271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurological manifestations in lysosomal storage disorders - from pathology to first therapeutic possibilities.
    Hoffmann B; Mayatepek E
    Neuropediatrics; 2005 Oct; 36(5):285-9. PubMed ID: 16217702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emptying the stores: lysosomal diseases and therapeutic strategies.
    Platt FM
    Nat Rev Drug Discov; 2018 Feb; 17(2):133-150. PubMed ID: 29147032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-neuronopathic lysosomal storage disorders: Disease spectrum and treatments.
    Pastores GM; Hughes DA
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):173-82. PubMed ID: 25987171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ten plus one challenges in diseases of the lysosomal system.
    Grabowski GA; Whitley C
    Mol Genet Metab; 2017; 120(1-2):38-46. PubMed ID: 27923545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzyme replacement therapy and substrate reduction therapy in lysosomal storage disorders with neurological expression.
    Valayannopoulos V
    Handb Clin Neurol; 2013; 113():1851-7. PubMed ID: 23622408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of antibodies in enzyme treatments and therapeutic strategies.
    Bigger BW; Saif M; Linthorst GE
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):183-94. PubMed ID: 25987172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges.
    Desnick RJ; Schuchman EH
    Annu Rev Genomics Hum Genet; 2012; 13():307-35. PubMed ID: 22970722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glyco-engineering strategies for the development of therapeutic enzymes with improved efficacy for the treatment of lysosomal storage diseases.
    Oh DB
    BMB Rep; 2015 Aug; 48(8):438-44. PubMed ID: 25999178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stem Cell Therapy for the Central Nervous System in Lysosomal Storage Diseases.
    Siddiqi F; Wolfe JH
    Hum Gene Ther; 2016 Oct; 27(10):749-757. PubMed ID: 27420186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene transfer strategies for correction of lysosomal storage disorders.
    D'Azzo A
    Acta Haematol; 2003; 110(2-3):71-85. PubMed ID: 14583667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perspectives on gene therapy for lysosomal storage diseases that affect hematopoiesis.
    Grabowski GA
    Curr Hematol Rep; 2003 Jul; 2(4):356-62. PubMed ID: 12901334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases.
    Pchelina SN; Nuzhnyi EP; Emelyanov AK; Boukina TM; Usenko TS; Nikolaev MA; Salogub GN; Yakimovskii AF; Zakharova EY
    Neurosci Lett; 2014 Nov; 583():188-93. PubMed ID: 25265039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone marrow transplantation and gene therapy for lysosomal storage diseases.
    Hoogerbrugge PM; Valerio D
    Bone Marrow Transplant; 1998 Apr; 21 Suppl 2():S34-6. PubMed ID: 9630322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases.
    Hemsley KM; Hopwood JJ
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S118-23. PubMed ID: 20040322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The status of hematopoietic stem cell transplantation in lysosomal storage disease.
    Malatack JJ; Consolini DM; Bayever E
    Pediatr Neurol; 2003 Nov; 29(5):391-403. PubMed ID: 14684234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and management of infusion-related hypersensitivity reactions to enzyme replacement therapy for lysosomal diseases: The role of desensitization.
    Aranda CS; Ensina LF; Nunes IC; Mallozi MC; Mendes C; Martins AM; Solé D
    J Allergy Clin Immunol Pract; 2016; 4(2):354-6. PubMed ID: 26776371
    [No Abstract]   [Full Text] [Related]  

  • 40. [Therapy of lysosomal storage diseases: update and perspectives].
    Lara-Aguilar RA; Juárez-Vázquez CI; Medina-Lozano C
    Rev Invest Clin; 2011; 63(6):651-8. PubMed ID: 23650678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.